Clinical Trial Update: Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency [Phase 3]

View source ↗

Summary

Phase 3 long-term safety extension study of LUM-201 in children with growth hormone deficiency; the trial is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• LUM-201

Snippet

Sponsor: Lumos Pharma | Conditions: Growth Hormone Deficiency (GHD) | Phase 3 | Status: NOT_YET_RECRUITING